Kymera Therapeutics, Inc. (KYMR) on Monday said the U.S. Food and Drug Administration has granted Fast Track designation to its investigational drug KT-621 for the treatment of moderate to severe eosinophilic asthma.
KT-621 is currently being evaluated in two Phase 2b studies, including the BREADTH trial in eosinophilic asthma, with data expected in late 2027. The company is also conducting the BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis, with results anticipated by mid-2027.
Kymera noted that KT-621 had previously received Fast Track designation in atopic dermatitis.
Shares of Kymera Therapeutics closed at $85.05 on Friday, down 2.63%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.